

# Gemini Stock Analysis Report

---

Okay, I will analyze the provided report on TORNTPHARM.NS using the requested step-by-step approach for a positional trade setup.

## Step 1: Audit the Data

- **Data Present:** Daily price chart (3 years), Relative Strength Analysis, EMA Crossover Summary and chart, Bollinger Bands Summary and chart, Supertrend Summary and chart, MACD Summary and chart, Volatility Squeeze Summary and chart, RSI-Volume Summary and chart, Long term and Short term Fundamental Analysis
- **Data Missing:** Weekly Charts
- **Confidence Level:** Medium. The provided report offers a good range of technical indicators and fundamental data, but lacks a weekly chart for a broader perspective.

## Step 2: Analyze the Setup

### Price Structure and Trend:

- The daily chart shows a generally upward trend over the past 3 years.
- The EMA crossover analysis indicates a "Strong Uptrend," with the price trading above its 20, 50, and 200-day EMAs. The golden cross also occurred around 2222.50 in December 2023
- The Supertrend indicator currently shows an uptrend with a recent signal identified on 2025-11-10.

### Momentum:

- The MACD Summary indicates a bearish trend and weakening momentum. Also, a bearish divergence was detected
- RSI is at 59.37 which indicates that the stock is neither overbought nor oversold

### Relative Strength:

- The RS score of 53.2 indicates that the stock is outperforming benchmark in the short term, and is a weakening leader

### Volatility:

- Volatility Squeeze Summary indicates the presence of volatility squeeze, suggesting a potential future price move.

## Step 3: Formulate the Recommendation

Based on the data, the overall trend is still bullish, but with some signs of slowing momentum and increased volatility. The bullish case is based on a long-term uptrend supported by multiple EMAs, Supertrend, and a recent buy signal. However, the conflicting signal from the MACD and Volatility squeeze indicates uncertainty. Therefore, the current setup needs to be monitored for confirmation.

### Recommendation: NO (Conditional Plan)

The current conditions make an immediate entry too risky. However, a potential trade setup could emerge if the momentum indicators realign with the overall bullish trend and the volatility squeeze resolves favorably.

- **Condition to Buy:** Close above 3850 (confirmation that the bullish trend is continuing and the period of

# Gemini Stock Analysis Report

- volatility is over)
- **Entry Price:** 3850
- **Stop Loss:** 3700 (Below EMA 50 and the breakout level)
- **Take Profit:** 4235 (5% gain)

## News & Analyst Targets

Okay, I will act as a stock research analyst and provide you with the latest information on Torrent Pharmaceuticals (TORNTPHARM). I will search for recent news, brokerage ratings, and analyst targets.

Here's a summary of the latest information on Torrent Pharmaceuticals (TORNTPHARM):

### 1. Latest News for TORNTPHARM this week:

- **Strong Financial Performance:** Torrent Pharmaceuticals reported strong Q2 FY'26 results with total revenues reaching Rs. 3,302 crore. (Source: Tickertape)
- **Analyst Recognition:** In December 2025, Torrent Pharmaceuticals was identified as one of seven large-cap companies posting their highest quarterly profits in the last 10 quarters. The company reported a net profit of Rs 591 crore for the September 2025 quarter.
- **Stock Performance:** As of December 19, 2025, Torrent Pharmaceuticals was trading at INR 3,800.30, a 1.08% increase compared to its previous closing price. (Source: Mint)
- **Derivatives Market Activity:** A surge in open interest in Torrent Pharmaceuticals' derivatives segment was observed, indicating evolving market positioning. (Source: The Mojo Times)

### 2. Brokerage Upgrades and Downgrades for TORNTPHARM:

- **BofA Securities Upgrade (November 2025):** BofA Securities upgraded Torrent Pharma from Neutral to Buy, raising the price target to INR 4,000 from INR 3,700. This followed strong Q2 results and projected earnings growth. The JB deal was highlighted as a significant growth catalyst. (Source: Investing.com, BofA Securities)
- **MarketsMOJO Downgrade (April 2024):** MarketsMOJO downgraded Torrent Pharmaceuticals to "Hold," citing expensive valuation and a high PEG ratio, despite strong management efficiency and positive financial results. (Source: MarketsMOJO)
- **JPMorgan Upgrade (June 2025):** JPMorgan upgraded Torrent Pharma to Overweight with a target price of INR 3,800. (Source: YouTube)

### 3. Other News Impacting TORNTPHARM:

- **JB Chemicals Acquisition:** Torrent Pharma's acquisition of a controlling stake in JB Chemicals and Pharmaceuticals is a major strategic move. Recent regulatory approvals have cleared the way for Torrent to acquire a 46% stake. (Source: Business Standard, Investing.com, Vibes Of India)
- **US Generic Drug Tariffs:** Relief among Indian drug companies as the US is not expected to impose additional tariffs on generic drugs. (Source: The Economic Times)

### 4. Analyst Targets for TORNTPHARM:

Here's a table summarizing recent analyst price targets:

Source	Target Price (INR)
Wall Street Analysts (Average)	4,073.01
Wall Street Analysts (Low)	3,565.3
Wall Street Analysts (High)	4,599
TradingView (Average)	4,043.92-4045.57
TradingView (Max Estimate)	4,500

# Gemini Stock Analysis Report

---

Source	Target Price (INR)
TradingView (Min Estimate)	3,530
Prabhudas Lilladher	2,250
BofA Securities	4,000
JPMorgan	3,800

## Important Considerations:

- **Valuation:** Some analysts believe Torrent Pharma is currently overvalued.
- **Growth Drivers:** Key growth drivers include strong performance in branded markets, the JB Chemicals acquisition, and potential synergies.
- **Challenges:** Challenges remain in the US market due to a lack of recent product launches.

**Disclaimer:** As a stock research analyst, this information is for informational purposes only and should not be considered financial advice. Please consult with a qualified financial advisor before making any investment decisions.


# Stock Detailed Analysis Report

**TORNTPHARM.NS**

Current Price: ₹3800.30

Generated: 2025-12-20 20:45

# TORNTPHARM.NS - 3 Year Daily Price Chart



## Long-term Fundamental Analysis (4 Years)

Metric	Is Growing?	Accelerating?	1Y Growth	3Y CAGR
Revenue	Yes	No	7.15%	10.36%
Net Income	Yes	No	15.39%	34.98%
ROE	Yes	No	4.22%	24.48%
EPS	Yes	No	15.39%	34.98%

## Short-term Fundamental Analysis (6 Quarters)

Metric	Is Growing?	Recent QoQ	Avg QoQ
Revenue	Yes	3.77%	3.55%
Net Income	Yes	7.85%	6.98%
ROE	Yes	6.57%	7.65%
EPS	Yes	7.78%	6.01%

# TORNTPHARM.NS - Relative Strength Analysis

## == OVERVIEW ==:

Benchmark Index:	^CNXPHARMA
Sector:	Pharma
Classification:	<b>Weakening Leader</b>
RS Score:	53.2/100
:	

## == RS RATIOS ==:

1M RS:	<b>1.018 [Leader]</b>
3M RS:	<b>1.039 [Leader]</b>
6M RS:	<b>1.131 [Leader]</b>
1Y RS:	<b>1.096 [Leader]</b>
:	


## == TURNAROUND ANALYSIS ==:

Turnaround Status:	<b>Not Detected</b>
:	


## SIGNAL CRITERIA::

✗ Emerging RS:	<b>Not accelerating</b>
✗ Medium-term Lagging:	<b>Not lagging</b>
✗ Performance Improving:	<b>Not improving</b>


**Relative Strength Analysis: TORNTPHARM.NS vs ^CNXPHARMA**  
**Classification: Weakening Leader**  
**Price Performance Comparison (Normalized)**



**RS Ratio Trends (Multiple Timeframes)**



**RS Composite Score Timeline**



## **TORNTPHARM.NS - EMA Crossover Summary**

<b>EMA 20:</b>	3761.47
<b>EMA 50:</b>	3707.97
<b>EMA 200:</b>	3500.04
<b>Trend Status:</b>	<b>Strong Uptrend</b>
<b>Golden Cross Date:</b>	2023-12-22 00:00:00
<b>Golden Cross Price:</b>	2222.50


# TORNTPHARM.NS EMA Crossover Analysis



## **TORNTPHARM.NS - Bollinger Bands Summary**

<b>Current Price:</b>	3800.30
<b>Upper Band:</b>	3818.16
<b>Middle Band (SMA 20):</b>	3761.24
<b>Lower Band:</b>	3704.33
<b>%B:</b>	0.8431
<b>Band Width:</b>	0.0303
<b>Status:</b>	Upper Half
<b>Signal:</b>	None
<b>Recent Signal 1:</b>	<b>Buy Signal at 2025-10-06 00:00:00</b>

## TORNTPHARM.NS Bollinger Bands (20, 2) Analysis




## **TORNTPHARM.NS - Supertrend Summary**

**Status:** UPTREND (Buy)

**Supertrend Value:** 3632.16

**Signal Identified On:** 2025-11-10

### Supertrend Analysis for TORNTPHARM.NS (Period: 14, Multiplier: 3.0, Interval: 1d)




## **TORNTPHARM.NS - MACD Summary**

<b>MACD Line:</b>	22.57
<b>Signal Line:</b>	25.94
<b>Histogram:</b>	-3.37
<b>Trend:</b>	<b>Bearish</b>
<b>Momentum:</b>	<b>Weakening</b>
<b>Signal:</b>	None
<b>Divergences Detected:</b>	1
└ <b>Bearish Divergence:</b>	Date: 2025-12-19 00:00:00, Price: 3800.30

### TORNTPHARM.NS Price





### TORNTPHARM.NS MACD (12, 26, 9)



## **TORNTPHARM.NS - Volatility Squeeze Summary**

<b>BB Width:</b>	0.0303
<b>ATR:</b>	61.0286
<b>Total Signals:</b>	40
<b>Signal 1:</b>	BB Squeeze + ATR Contraction at 2025-12-15 00:00:00 (Price: 3780.00)
<b>Signal 2:</b>	BB Squeeze + ATR Contraction at 2025-12-16 00:00:00 (Price: 3780.00)
<b>Signal 3:</b>	BB Squeeze + ATR Contraction at 2025-12-17 00:00:00 (Price: 3780.00)
<b>Signal 4:</b>	BB Squeeze + ATR Contraction at 2025-12-18 00:00:00 (Price: 3780.00)
<b>Signal 5:</b>	BB Squeeze at 2025-12-19 00:00:00 (Price: 3800.30)

# TORNTPHARM.NS - Volatility Squeeze Analysis



# **TORNTPHARM.NS - RSI-Volume Summary**

<b>Current RSI:</b>	59.37
<b>Current Volume:</b>	150394
<b>Volume MA 20:</b>	192324
<b>Bullish Divergences:</b>	2
<b>Bearish Divergences:</b>	1
<b>Bullish Div 1:</b>	Date: 2024-11-19 00:00:00, Price: 3094.85
<b>Bullish Div 2:</b>	Date: 2025-02-14 00:00:00, Price: 3013.85
<b>Bearish Div 1:</b>	Date: 2025-04-28 00:00:00, Price: 3335.00

# TORNTPHARM.NS RSI-Volume Divergence Analysis

